Draft Guidance on Chlordiazepoxide Hydrochloride

This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs.

Active Ingredient: Chlordiazepoxide hydrochloride

Dosage Form; Route: Capsule; oral

Recommended Studies: Two studies

1. Type of study: Fasting
   Design: Single-dose, two-way crossover in vivo
   Strength: 25 mg
   Subjects: Males and non-pregnant, non-lactating females, general population
   Additional comments: Applicants may consider using a parallel study design due to its long half-life. For long half-life drug products with low intra-subject variability in distribution and clearance, an area under the plasma concentration time curve (AUC) truncated to 72 hours may be used in place of AUC_{0-t} or AUC_{0-∞}. For either a crossover or parallel study, sample collection time should be adequate to ensure completion of gastrointestinal transit of the drug product and absorption of the drug substance. Collect sufficient blood samples in the bioequivalence studies to adequately characterize peak drug concentration and time to reach peak drug concentration.

2. Type of study: Fed
   Design: Single-dose, two-way crossover in vivo
   Strength: 25 mg
   Subjects: Males and non-pregnant, non-lactating females, general population
   Additional comments: See comments above

Analyte to measure (in appropriate biological fluid): Chlordiazepoxide in plasma

Bioequivalence based on (90% CI): Chlordiazepoxide

Waiver request of in vivo testing: 5 mg, and 10 mg based on (i) acceptable bioequivalence studies on the 25 mg strength, (ii) proportional similarity of the formulations across all strengths and (iii) acceptable in vitro dissolution testing of all strengths

Dissolution test method and sampling times: The dissolution information for this drug product can be found on the FDA-Recommended Dissolution Methods website available to the public at the following location: http://www.accessdata.fda.gov/scripts/cder/dissolution/. Conduct comparative

Recommended Sept 2019
dissolution testing on 12 dosage units each of all strengths of the test and reference products. Specifications will be determined upon review of the abbreviated new drug application.